NCR Voyix CEO David Wilkinson to Present at the Morgan Stanley TMT Conference on March 5
NCR Voyix Corporation (NYSE: VYX), a leading provider of technology solutions to the retail, restaurant and digital banking industries, announced today that David Wilkinson, NCR Voyix's CEO, will participate in a fireside chat at the Morgan Stanley TMT Conference. Wilkinson's presentation will take place Tuesday, March 5 at 1:20 p.m. PST, and will be available live and via replay at the company's investor relations website at https://investor.ncrvoyix.com.
About NCR Voyix
NCR Voyix Corporation (NYSE: VYX) is a leading global provider of digital commerce solutions for the retail, restaurant and digital banking industries. NCR Voyix transforms retail stores, restaurant systems and digital banking experiences with comprehensive, platform-led SaaS and services capabilities. NCR Voyix is headquartered in Atlanta, Georgia, with approximately 15,000 employees and customers in 35 countries.
XSOOH has always been at the forefront of hair care innovation, striving to deliver cutting-edge products that enhance the way customers achieve their desired looks. In a world where time is precious, XSOOH proudly announces the launch of the...
In a landmark event signaling its ambitious foray into the biopharmaceutical sector, LOTTE BIOLOGICS, under the leadership of CEO Richard W. Lee, held a groundbreaking ceremony for its inaugural plant at the Songdo Bio Campus in Incheon International...
On June 29, the "Gather Great Wisdom to Shape the Future of Intelligent Manufacturing?Special Exhibition on Design Intelligence and High Quality Development", hosted by the China Academy of Art (CAA), opened at the National Museum of China in...
Intermap Technologies ("Intermap" or the "Company"), a global leader in 3D geospatial products and intelligence solutions, announces a new financing. The Company is offering up to a maximum of 4,300,000 Class "A" common shares of the Company...
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to...
